CARE upgrades rating of Wockhard’s long term loans to AA

21 Apr 2015 Evaluate

Credit rating agency, CARE Ratings has upgraded rating of Wockhard’s long term loans from “AA-” to “AA” on partial resolution of regulatory issues and improvement in revenues from contract manufacturing.

The revision factors in partial resolution of regulatory issues along with expectation of these issues being fully resolved in the near term. It also takes into account partial commercialisation of the pharma company’s upcoming new facility.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

 

Wockhardt Share Price

1360.10 28.75 (2.16%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×